Ethics and Public Policy Center study finds higher mifepristone adverse event rate
Updated
Updated · The Wall Street Journal · May 10
Ethics and Public Policy Center study finds higher mifepristone adverse event rate
6 articles · Updated · The Wall Street Journal · May 10
Using insurance claims on more than 850,000 prescribed abortions from 2017 to 2023, researchers said nearly 11% of women had serious complications within 45 days.
The report said that was at least 22 times the under-0.5% rate cited in clinical trials on the drug label, and that risks rose after the FDA ended in-person dispensing.
It said remote dispensing made inappropriate use in ectopic pregnancies three to six times more likely, and argued restoring in-person prescribing would reduce health risks and coercion concerns.
With experts and regulators presenting conflicting safety data, what are the true risks of taking the abortion pill today?
If clinical trials show mifepristone is safe, why does a recent study report a 22-fold increase in serious complications?
As abortion pills move to mail-order, are crucial safeguards against deadly complications and coercion being lost?